• admin@condrug.com
  • Mon - Sat: 8.00 am - 7.00 pm

We develop solutions for your clinical data needs

Linkedin-in Link
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Whatsapp

+1 (877) 703-6664

Free to Use
ConDrug
  • Workspace
  • Drug Safety Data
  • Blog
  • About Us
  • Contacts

Blog

Pharmacovigilance
AI-driven pharmacovigilance platform analyzing real-world drug safety data and adverse event reports

Why AI-Driven Pharmacovigilance Is Now Essential for Modern Drug Safety

Discover why AI-driven pharmacovigilance is no longer optional. Learn how AI automates case intake, enhances signal detection, and enables real-time benefit–risk decisions to keep pace with complex drug safety demands and regulatory expectations.

Small Molecule Drugs
Abstract 3D molecular structure overlaid with neural network graphics illustrating AI-driven small molecule drug discovery

AI-Designed Small Molecule Drugs: How Machine Learning Is Rewiring Drug Discovery

Discover how AI and machine learning are transforming small molecule drug discovery—from generative models and property prediction at scale to on-demand molecule design that compresses R&D timelines from years to months.

New Drugs
Person using an intranasal zavegepant migraine spray for fast, non‑vasoconstrictive CGRP blockade

Zavegepant Nasal Spray for Migraine: How It Works, Benefits & Clinical Data

Learn what zavegepant is, how this intranasal CGRP receptor antagonist works for acute migraine treatment, and why its non‑vasoconstrictive, needle‑free nasal spray delivery may benefit patients with nausea or cardiovascular risk factors.

Protein-Peptide Drugs
Illustration of tirzepatide dual GIP and GLP‑1 receptor signaling for weight loss and metabolic control

What Is Tirzepatide? Dual GIP/GLP‑1 Agonist Mechanism, Benefits & Weight Loss Results

Learn what tirzepatide is, how its dual GIP and GLP‑1 receptor agonism works, and why it delivers bariatric surgery–level weight loss and powerful metabolic benefits in obesity and type 2 diabetes.

Pharmacovigilance

From AI Pilots to Scalable Pharmacovigilance: Building AI-Ready Drug Safety Workflows

Learn how to move beyond AI pilots in pharmacovigilance and design AI-ready drug safety workflows. Explore end-to-end safety pipelines for case intake, triage, signal detection, and decision support that are compliant, scalable, and deliver real-world impact.

New Drugs

What Is Deucravacitinib? Mechanism, Benefits & Role in Plaque Psoriasis

Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and why it’s reshaping treatment for moderate‑to‑severe plaque psoriasis with biologic‑like efficacy and a differentiated safety profile.

Small Molecule Drugs

PROTAC Small Molecules in Oncology: Targeted Protein Degradation for “Undruggable” Cancer Targets

Learn how PROTAC small molecules are redefining cancer therapy by harnessing targeted protein degradation to eliminate “undruggable” oncogenic drivers, overcome resistance, and expand the frontier of small molecule oncology.

Protein-Peptide Drugs

From Lab Tool to Protein Drug: How Cas9 Became a Programmable CRISPR Therapeutic

Discover how CRISPR–Cas9 is evolving from a genome-editing lab tool into a programmable protein drug. Explore viral vectors, lipid nanoparticles, and peptide-based delivery strategies that enable safe, one‑time gene editing therapies for diseases like sickle cell and inherited retinal disorders.

Pharmacovigilance

AI-Powered Pharmacovigilance: Building an AI-Ready Drug Safety System

Learn how AI-powered pharmacovigilance transforms drug safety from manual, reactive case processing to real-time, data-driven surveillance using NLP, machine learning, and intelligent automation—while maintaining scientific rigor and regulatory compliance.

Pharmacovigilance

AI-Driven Digital Safety Twins in Pharmacovigilance: Transforming Drug Safety Monitoring

Discover how AI-powered digital safety twins are reshaping pharmacovigilance by turning static safety profiles into real-time, learning risk models. Learn how virtual replicas of drugs, patients, and treatment pathways enable proactive risk prediction, dynamic stratification, and scenario simulation across the product lifecycle.

  • 1
  • 2
  • 3
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 20
  • 21
  • 22
Categories
  • New Drugs (53)
  • Pharmacovigilance (73)
  • Protein-Peptide Drugs (41)
  • Small Molecule Drugs (45)
Tags
adverse drug reactions adverse event detection AI in drug safety AI in Healthcare AI in Pharmacovigilance artificial intelligence deucravacitinib drug discovery Drug Safety GIP GIP GLP-1 dual agonist GLP-1 GLP-1 agonist healthcare AI healthcare data incretin therapy Life Sciences Machine Learning machine learning in healthcare machine learning in pharma] metabolic disease metabolic health migraine treatment NLP obesity treatment peptide therapeutics pharmacovigilance pharmacovigilance automation PROTACs real-world data] real-world evidence signal detection small molecule design small molecule drugs SURPASS trials targeted protein degradation tirzepatide TYK2 inhibitor type 2 diabetes type 2 diabetes treatment weight loss weight loss drugs weight loss medication [AI drug discovery [AI pharmacovigilance
Recent Posts
  • Gefapixant for Chronic Cough: How This P2X3 Antagonist Is Changing Treatment
    17/12/2025
  • What Is Retatrutide? Triple Agonist Weight Loss Drug Explained (GLP‑1, GIP, Glucagon)
    17/12/2025
  • Ensifentrine for COPD: Dual PDE3/4 Inhibitor Mechanism, Benefits & Clinical Data
    17/12/2025
  • Home
  • Workspace
  • Contacts

Copyright © 2026 ConDrug All Rights Reserved.

Linkedin-in Handshake